anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Scrub typhus is a zoonotic disease caused by Orientia tsutsugamushi confined to East Asia including South Korea. It is characterized by fever, headache, rash, and eschar and the majority of patients without complications can recover with an early diagnosis and proper management with antibiotics. However, the increasing mortality rate of scrub typhus has been recently reported in Southeast Asia. Severe complications can be manifested by respiratory distress syndrome, renal failure, hepatic failure, and cardiovascular disease. Especially, cardiovascular complications can lead to cardiogenic shock and sudden cardiac arrest. Therefore, the association and predictors for scrub typhus induced cardiovascular disease should be investigated to provide a timely and appropriate diagnosis and to reduce the mortality rate of complicated scrub typhus infection. Therefore, investigators prospectively investigate the association and predictors of cardiovascular disease in the participants with scrub typhus infection admitted to 3rd referral centers in South Korea.
BACKGROUND: Juvenile idiopathic arthritis (JIA) comprises a whole spectrum of chronic arthritis starting before 16 years of age. The study aims to explore the clinical and demographic descriptors, treatment, and disease progression of enthesitis-related arthritis (ERA) in comparison with juvenile-onset spondyloarthritis (SpA).
METHODS: Cross-sectional analysis of consecutive patients in two dedicated clinics, with a single visit and retrospective case-notes review. Arthritis, enthesitis and sacroiliitis were evaluated by scoring disease activity and damage. Continuous variables were reported by median, interquartile range; categorical variables were reported by the frequency comparison of the two groups.
RESULTS: Thirty-three cases were included, being 23 (69.7%) with ERA. The median age at diagnosis was 12.5 y (SpA) vs. 9 y (ERA) (p < 0.01); the time from symptom onset to diagnosis was 5.5 y (SpA) vs. 1.5 y (ERA) (p < 0.03). In both groups, the predominant presentation was a single joint or < 5 lower limb joints and asymmetric involvement, with a high frequency of enthesitis. There was a higher frequency of mid-tarsal and ankle synovitis in the ERA group and hip involvement in those with SpA. The comparison of the frequency of spine symptoms at presentation, 30% SpA vs. 21.7% ERA (p = 0.7), was not significant, and radiographic progression to spinal involvement occurred in 43.5% of ERA patients. The median time for spinal progression and age at onset was 2.2 and 12 y for ERA, and 4 and 16.5 y for SpA, respectively. Activity and damage scores were not significantly different between the groups. Treatment comparison resulted in 91.3% of ERA and 100% SpA being treated, predominantly with NSAIDs in both groups, followed by DMARDs and biologics, with a higher frequency of biologics in SpA.
CONCLUSION: The main differences were the late diagnoses of SpA, and the hip and spine involvement, with higher frequency of biologic treatment in juvenile-onset SpA compared to ERA.
PURPOSE:To provide a cosmetic containing a liquid fluorocarbon, having excellent skin-protecting property and skin-respiration performance and giving a durable make-up. CONSTITUTION:A liquid fluorocarbon, especially a liquid fluorinated pitch is included in a cosmetic in an amount of 0.1-30wt.%, especially 5-20wt.%. Liquid fluorinated pitch is a colorless and odorless transparent substance having excellent water resistance and oil resistance and extremely stable in living body. Furthermore, since it is a highly branched polycyclic compound, it has high oxygen-dissolution ratio and excellent air-permeability and is applicable without lowering the skin respiration. The liquid fluorinated pitch can be produced e.g. by directly reacting pitch with fluorine at 0-350 deg.C and keeping the reaction product at a temperature higher than the reaction temperature and below 550 deg.C or by reacting pitch with fluorine while heating the pitch in fluorine atmosphere to the final temperature selected in the range of 200-550 deg.C.
Epilepsy is a common neurological disorder characterized by recurrent seizures with excessive and abnormal neuronal discharges. Epileptogenesis is usually involved in neuropathological processes such as ion channel dysfunction, neuronal injury, inflammatory response, synaptic plasticity, gliocyte proliferation and mossy fiber sprouting, currently the pathogenesis of epilepsy is not yet completely understood. A growing body of studies have shown that epigenetic regulation, such as histone modifications, DNA methylation, noncoding RNAs (ncRNAs), N6-methyladenosine (m6A) and restrictive element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) are also involved in epilepsy. Through epigenetic studies, we found that the synaptic dysfunction, nerve damage, cognitive dysfunction and brain development abnormalities are affected by epigenetic regulation of epilepsy-related genes in patients with epilepsy. However, the functional roles of epigenetics in pathogenesis and treatment of epilepsy are still to be explored. Therefore, profiling the array of genes that are epigenetically dysregulated in epileptogenesis is likely to advance our understanding of the mechanisms underlying the pathophysiology of epilepsy and may for the amelioration of these serious human conditions provide novel insight into therapeutic strategies and diagnostic biomarkers for epilepsy to improve serious human condition.
PURPOSE:To obtain a sustained release preparation of theophylline, containing theophylline or a derivative or a salt thereof, an insoluble high polymer and an enteric high polymer. CONSTITUTION:A sustained release table of theophylline, containing 10-70wt.% theophylline or a derivative (e.g. aminophylline, choline theophylline or diphylline) a salt (e.g. theophylline calcium salicylate), 10-70wt.% insoluble high polymer (e.g. ethyl cellulose, aminoalkyl methacrylate copolymer, polyvinyl acetate or polyvinyl chloride) and 5-55wt.% enteric high polymer (e.g. phthalic acid cellulose acetate or maleic acid cellulose acetate). The tablet finally collapses completely by matrix release in the stomach and by dissolution and matrix release in the intestine and releases the total amount of theophylline to provide desirable blood concentration.
PURPOSE:To recover and purify the titled compound from precipitates, by dissolving an extract from a plant body containing lansic acid in a hydrophilic organic solvent, subsequently adding a bivalent or trivalent metal oxide, etc., adjusting the pH to >=7 to precipitate the titled compound. CONSTITUTION:A lansic acid-containing extract obtained from Lansium domesticum Jack var. Duke or Lansium domesticum Jack var. Langsat is dissolved in a hydrophilic organic solvent, e.g. methanol, ethanol, acetone, etc., and then a bivalent or trivalent metal oxide, hydroxide or salt, e.g. calcium oxide, magnesium oxide, aluminum chloride, etc., is added and mixed therewith. When the mixture solution is acidic, a base is then added to adjust the pH to >=7 and the formed precipitates are obtained by separation to recover the aimed lansic acid from the precipitates. The precipitates are preferably suspended in a hydrophobic organic solvent or a mixed solvent of a hydrophobic organic solvent and water and an inorganic acid is then added to dissolve the precipitates. The resultant solution is extracted with a hydrophobic organic solvent and the solvent is distilled away to recover the titled compound.
Tuberculosis (TB) is the leading infectious killer globally and a major cause of illness and suffering. The World Health Organization has prioritized TB preventive therapy (TPT) for people with latent TB infection (LTBI) as a key strategy for controlling the epidemic. Prevention of TB with isoniazid preventive therapy (IPT) is effective and reduces morbidity and mortality, and has been the mainstay of TB prevention for decades. But for an intervention with an excellent evidence of efficacy, global uptake has been abysmal. Completion rates for IPT when it is administered are poor (Gillespie 2008; Durovni 2010), with a large proportion of patients unable to complete treatment (McClintock 2017; Sterling 2011). While uptake is influenced by a variety of factors, a critical element has been the duration of IPT, with adherence falling sharply over time in clinical trials and practice. Shorter course regimens have a much higher completion rate and are more acceptable to patients, clinicians, and programs.
This is a parallel 3-group, multicenter, prospective, randomized, single-blind (evaluator) controlled pilot trial, with a 38- week follow-up. Patients diagnosed with bipolar disorder (BD) according to DSM -5 criteria for mild depression or subsyndromal depressive symptoms are assigned to one of the following 3 treatment groups: 1) psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT); 2) psychopharmacological treatment plus structured group psychoeducation; 3) treatment as usual (TAU), including standard psychiatric care with standard pharmacologic treatment. After written informed consent is signed, patients meeting the inclusion criteria are randomized (2:2:1 ratio) through a Random Allocation Software. All three groups are assessed at baseline (t0), immediately after completing the program (t1; 8 weeks) and at follow-up six months after randomization. The assessments include the following variables: depression, anxiety, general and social cognition, global functioning, BDNF, and other clinical variables. The evaluator who collected the biomarkers and the clinical and psychometric data will be blind to treatment. The interrater variability between all researchers will be checked.
Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.
Multi-cytokine-producing Th9 cells secrete IL-9 and type 2 cytokines and mediate mouse and human allergic inflammation. However, the cytokines that promote a multi-cytokine secreting phenotype have not been defined. Tumor necrosis factor superfamily member TL1A signals through its receptor DR3 to increase IL-9. Here we demonstrate that TL1A increases expression of IL-9 and IL-13 co-expressing cells in murine Th9 cell cultures, inducing a multi-cytokine phenotype. Mechanistically, this is linked to histone modifications allowing for increased accessibility at the Il9 and Il13 loci. We further show that TL1A alters the transcription factor network underlying expression of IL-9 and IL-13 in Th9 cells and increases binding of transcription factors to Il9 and Il13 loci. TL1A-priming enhances the pathogenicity of Th9 cells in murine models of allergic airway disease through the increased expression of IL-9 and IL-13. Lastly, in both chronic and memory-recall models of allergic airway disease, blockade of TL1A signaling decreases the multi-cytokine Th9 cell population and attenuates the allergic phenotype. Taken together, these data demonstrate that TL1A promotes the development of multi-cytokine Th9 cells that drive allergic airway diseases and that targeting pathogenic T helper cell-promoting cytokines could be an effective approach for modifying disease.
The invention belongs to the field of wine brewing, and discloses a four-ingredient medicinal liquor capable of prolonging life span. The four-ingredient medicinal liquor is prepared from 900g of pig kidney, 50g of eucommia ulmoides, 20g of cortex cinnamomi, 20g of wolfberry, and 2500ml of 60% Vol. liquor. A preparation method of the four-ingredient medicinal liquor comprises following steps: 900g of pig kidney is cut into small pieces for further use; 50g of eucommia ulmoides, 20g of cortex cinnamomi, and 20g of wolfberry are smashed for further use; the materials obtained via the two steps are immersed in the 2500ml of 60% Vol. liquor, an obtained mixture is sealed, and residue is removed after 15 days of immersing so as to obtain a finished product. The four-ingredient medicinal liquor is capable of prolonging life span, invigorating kidney, and strengthening Yang; and is mainly used for treating kidney deficiency and seminal emission, waist and knee pain, body and mind tiredness, weakness, tinnitus, and the like.
PURPOSE:To prepare Sasa albo-marginata for extraction by heating an aqueous solution of NaHCO3, NaCl and NaCO3, putting the Sasa thereinto, stirring the treating solution while keeping it to a prescribed temperature, subsequently thoroughly drying it and storing it in a well-ventilated place. CONSTITUTION:In storage of raw leaves of Sasa albo-marginata used for extraction of its extract containing chlorophyll, a treating solution composed of an aqueous solution containing sodium bicarbonate, sodium chloride and sodium carbonate is put into a treating tank and heated to about 80 deg.C. A suitable amount of raw leaves of Sasa albo-marginata are then put thereinto and the treating solution is stirred while keeping the temperature to 70 deg.C-80 deg.C. The leaves of Sasa are subsequently taken out and water is drained off. Thorough drying is carried out by using a drier and the resultant dried leaves are stored in a wellventilated place while avoiding sunshine. Active components of Sasa albo-marginata can be stably preserved thereby.
The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
Glanzmann thrombasthenia and clotting factor VII deficiency are rare autosomal recessive bleeding disorders. But the occurrence of both in the same person is an extremely rare phenomenon. Here, we present the case of a young female from Sindh, Pakistan that got diagnosed with Glanzmann thrombasthenia and concomitant moderate factor VII deficiency, a combination not previously reported in the country. The patient exhibited typical clinical manifestations including menorrhagia, nasal bleeds, and prolonged bleeding after minor injuries, compounded by a positive family history and consanguinity. Laboratory investigations revealed marked anemia, prolonged bleeding time, and abnormal platelet aggregation studies consistent with Glanzmann thrombasthenia. The identification of this rare combination relied on comprehensive clinical evaluation, emphasizing the importance of family history in suspected cases. Management involved platelet transfusions, tranexamic acid, and Factor VII replacement, resulting in clinical improvement.
PURPOSE: To obtain a pretreating agent for dyeing hair capable of expecting hair dyeing effects on selective dyeing of the hair in using an avidin- or a biotin-binding pigment as a dyeing agent. CONSTITUTION: This pretreating agent for dyeing hair contains an antihair antibody containing biotin or avidin bound thereto. The antihair antibody containing the biotin or avidin bound thereto as the pretreating agent is applied to the hair and an avidin- (or a biotin)-binding pigment is then applied to sufficiently manifest the hair binding power of the antihair antibody. Furthermore, the hair can be dyed with higher hair dyeing effects than those of hair dyeing simply with the avidin or biotin without using the antibody. The biotin-binding antibody is obtained by previously activating carboxyl group of the biotin and then introducing the activated carboxyl group into the free amino group in the antibody.  The avidin-binding antibody is obtained by previously introducing N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) into the free amino group in avidin or the antibody, subsequently treating the resultant antibody with a reducing agent, producing free sulfhydryl group and reacting the prepared compound with the antibody or avidin into which the SPDP is introduced.
A wearable, self-contained drug infusion device is disclosed that is capable of achieving the precise flow rate control needed for dose-critical drugs such as insulin. In preferred embodiments of the device, at least two flow channels (76, 78) are utilized in conjunction with a series of valves (82) for providing a user with selectable, constant flow rate control. The device can be made with small dimensions so that it can be worn by the user with a minimum of discomfort and inconvenience. In addition, the simple mechanical nature of the device provides the user with close control over the flow rate, which is required for safe and effective delivery of insulin and other drugs. Also, the absence of electronic components allows the device to be manufactured inexpensively. The device is pro provided with a first channel (76) that is long and narrow, functioning as a flow restrictor. The first channel (76) is preferably provided in a serpentine pattern. A second channel (78) is also provided that has a larger cross section so that flow is not re restricted. A series of valves (82) are used to force the flow of fluid through a selectable portion of the serpentine portion of the first channel (76) before entering the remainder of the sec second channel (78) and flowing to the delivery cannula (48). In one embodiment of the device, a needle port is provided in fluid communication with the delivery cannula for delivering bolus injections. In another embodiment, a bolus button (100) is pro provided for delivering bolus injections. A flow restrictor (102) is preferably included in the bolus button to limit the rate at which the bolus button refills.
INTRODUCTION AND OBJECTIVES: Cohort studies reported controversial results regarding the long-term prognosis of patients with lean non-alcoholic fatty liver disease (NAFLD) compared to non-lean NAFLD patients. This updated meta-analysis aimed to estimate the magnitude of the association between lean body mass index and all-cause mortality risk in NAFLD patients.
MATERIALS AND METHODS: We systematically searched the EMBASE and MEDLINE databases from inception to March 2023 to identify observational studies that reported hazard ratio (HR) for all-cause mortality of patients with lean NAFLD versus those with non-lean, overweight, or obese NAFLD. Multivariable-adjusted hazard ratios (HRs) for all-cause mortality were pooled using a random effects model.
RESULTS: Fourteen studies with 94,181 NAFLD patients (11.3 % with lean NAFLD) and 7,443 fatal events over a median follow-up of 8.4 years (IQR, 6.6-17.4 years) were included. Patients with lean NAFLD had a higher risk of all-cause mortality than those with non-lean NAFLD (random-effects HR 1.61, 95 % CI 1.37-1.89; I2=77 %). The magnitude of this risk remained unchanged even after stratified analysis by measures of NAFLD diagnosis, study country, cohort setting, length of follow-up, adjustment with fibrosis stage/cirrhosis, and the Newcastle-Ottawa Scale. The risk was independent of age, sex, and cardiometabolic risk factors. Sensitivity analyses did not alter these findings. The funnel plot and Egger's test revealed no significant publication bias.
CONCLUSIONS: This meta-analysis revealed that lean NAFLD is associated with an approximately 1.6-fold increased mortality risk. Further studies are needed to unravel the existing but complex link between lean NAFLD and an increased risk of death.
Other reactions have included hepatic dysfunction including cholestasis and elevations in serum transaminase, genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. Agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, Stevens-Johnson syndrome, serum sickness, and arthralgia have been rarely reported.

In addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:

Toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive Coombs’ test, increased BUN, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated bilirubin, elevated LDH, eosinophilia, pancytopenia, neutropenia.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see DOSAGE AND ADMINISTRATION and OVERDOSAGE). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. 

The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials). 

A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 

The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. 

The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each participant will have the opportunity to walk on certain public space as the ROC training groups and interact with the therapist and caregivers depending on his/her motor abilities. The participants will also wear the head-mounted eye-tracker in one training session every week.